Niagen Bioscience, Inc. (NAGE)

NCM – Цена в реальном времени. Валюта: USD

3.85

-0.13 (-3.27%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.88

+0.03 (0.69%)

До открытия: May 13, 2026, 5:15 AM EDT

08.05.2026

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference Location: Jazz at Lincoln Center's Frederick P. Rose Hall Date: May 12, 2026 Format: Emerging Company Pavilion, a curated showcase of 8-10 select companies Management: Ozan Pamir, CFO.

06.05.2026

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates

Niagen Bioscience (NAGE) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago.

06.05.2026

Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript

06.05.2026

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million. Gross margin of 63.5%, reflecting continued strength in business mix. Net income of $6.3 million, incl.

04.05.2026

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #AtHomeInjection--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of its clinician-directed telehealth platform under Niagen™ Plus, enabling eligible patients in the U.S. to access prescription-only, pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride, NRCl) from home with the first-of-its-kind Niagen® At-Home Injection Kit. The launch m.

28.04.2026

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a new partnership with Olympia Pharmaceuticals, a state-of-the-art U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen® (patented nicotinamide riboside, NR) for the Company's Niagen Plus™ intravenous and injectable products. Olympia Pharmaceuticals joi.

22.04.2026

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 6, 2026.

Видео

No Data

There is no data to display

Пресс-релизы

06.05.2026

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

04.05.2026

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

28.04.2026

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a new partnership with Olympia Pharmaceuticals, a state-of-the-art U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen® (patented nicotinamide riboside, NR) for the Company's Niagen Plus™ intravenous and injectable products. Olympia Pharmaceuticals joi.

09.04.2026

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in the Company's flagship ingredient, Niagen®, now has a published United States Pharmacopeia (USP) dietary supplement ingredient monograph. This monograph reflects the scientific rigor behind Niagen and establishes.

Niagen Bioscience, Inc. (NAGE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates

Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Видео

No Data

Пресс-релизы

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates

Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Видео

No Data

Пресс-релизы

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

Search stocks

Niagen Bioscience, Inc. (NAGE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates

Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Видео

No Data

Пресс-релизы

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates

Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Видео

No Data

Пресс-релизы

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®